23
MAY
2013
NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer
Comments : Off
NW Bio Exhibit Will Describe DCVax Technology and Clinical Trial Progress at Annual Meeting of Over 25,000 Oncologists BETHESDA, Md., May 23, 2013 — Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that it will use its exhibit at this year’s American Society Of Clinical Oncology (ASCO) meeting in Chicago to highlight... Read More